Viscosalactone B
Viscosalactone B is an orally active LSD1 inhibitor with an IC50 of 970.27 nM. Viscosalactone B targets COX-2, inhibits cyclooxygenase activity, and inhibits p97 ATPase activity in a cysteine-dependent manner. Viscosalactone B can be used in cancer-related research such as prostate cancer, lung cancer, and breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 76938-46-0
- 分子式: C28H40O7
- 分子量:488.61
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
|
LSD1 970.27 nM (IC50) |
COX-2 |
p97 ATPase |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PC-3 | IC50 |
1.17 μM
|
Antiproliferative activity against human PC3 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay.
Antiproliferative activity against human PC3 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay.
|
36692618 |
| DU-145 | IC50 |
0.72 μM
|
Antiproliferative activity against human DU145 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay.
Antiproliferative activity against human DU145 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay.
|
36692618 |
| NCI-H460 | IC50 |
0.32 μg/mL
|
Antiproliferative activity against human NCI-H460 lung tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
Antiproliferative activity against human NCI-H460 lung tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
|
14575818 |
| HCT-116 | IC50 |
0.47 μg/mL
|
Antiproliferative activity against human HCT-116 colon tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
Antiproliferative activity against human HCT-116 colon tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
|
14575818 |
| SF-268 | IC50 |
0.45 μg/mL
|
Antiproliferative activity against human SF-268 CNS tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
Antiproliferative activity against human SF-268 CNS tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
|
14575818 |
| MCF7 | IC50 |
0.40 μg/mL
|
Antiproliferative activity against human MCF-7 breast tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
Antiproliferative activity against human MCF-7 breast tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.
|
14575818 |
体外実験
Viscosalactone B (0.25-32 µM; 72 h) inhibits DU145 cell proliferation partly through inhibiting LSD1, with an IC50 of 0.81 µM in DU145&shControl cells and 4.12 µM in DU145&shLSD1 cells[2].
Viscosalactone B (0.3-0.9 µM; 48 h) increases the levels of H3K9me1, H3K9me2, and H3K4me1 in DU145 cells in a concentration-dependent manner[2].
Viscosalactone B (compound 12) (48 h) inhibits the proliferation of NCI-H460, HCT-116, SF-268, and MCF-7 human tumor cell lines, with IC50 values of 0.32, 0.47, 0.45, and 0.40 µg/mL, respectively[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145&shLSD1 and DU145&shControl prostate cancer cell lines
-
Concentration:0.25, 0.5, 1, 2, 4, 8, 16, 32 µM
-
Incubation Time:72 h (TBT assay)
-
Result:LSD1 gene expression rates were 9.3% in DU145&shLSD1 cells and 99.7% in DU145&shControl cells.
Inhibited DU145&shControl cells with an IC50 of 0.81 µM and DU145&shLSD1 cells with an IC50 of 4.12 µM, approximately 5-fold less potent in LSD1-knockdown cells.
-
Cell Line:DU145 prostate cancer cells
-
Concentration:0.3, 0.6, 0.9 µM
-
Incubation Time:48 h
-
Result:Induced concentration-dependent accumulation of LSD1 substrates H3K9me1, H3K9me2, and H3K4me1 in DU145 cells.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (18-25 g)[2]
-
Dosage:30 mg/kg
-
Administration:intragastric (i.g.); for 21 days
-
Result:At 30 mg/kg, DU145 tumor growth was suppressed.
At 30 mg/kg, tumor weight was inhibited in BALB/c nude mice.
化学情報
-
CAS 番号 76938-46-0
-
分子量 488.61
-
分子式 C28H40O7
-
SMILES
C[C@]12[C@@]3([C@H]([C@H](CC2=O)O)O)[C@](C[C@]4([H])[C@]1([H])CC[C@]5([C@@]4([H])CC[C@]5([H])[C@@H]([C@@]6([H])CC(C)=C(C(O6)=O)CO)C)C)([H])O3
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Khairy A, et al. Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach. Scientific reports. 2022 Nov 09;12(1):19037. [Content Brief]
[2]. Yan G, et al. Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Invest New Drugs. 2023 Feb;41(1):134-141. [Content Brief]
[4]. Jayaprakasam B, et al. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life sciences. 2003 Nov 21;74(1):125-32. [Content Brief]
[5]. Santagata S, et al. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS chemical biology. 2012 Feb 17;7(2):340-9. [Content Brief]
[6]. Tao S, et al. Withaferin A Analogs That Target the AAA+ Chaperone p97. ACS chemical biology. 2015 Aug 21;10(8):1916-1924. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)